Key points are not available for this paper at this time.
Keywords: TGF-β, TGF-βRI kinase inhibitor, ALK5, galunisertib, LY2157299, cancer, clinical trials
Share your take
Add a clinician perspective alongside expert commentary.
Lahn et al. (Sat,) studied this question.